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pGuidelines for clinical care are derived most com-
monly from large clinical trials involving thousands
of patients. These trials are usually conducted to
test hypotheses that have been developed from
interesting clinical observations and innovative pilot
trials. In this issue of iJACC, Prati et al. (1) describe
interesting hypothesis-generating observations in pa-
tients with ST-segment elevation myocardial infarc-
tion (STEMI).
See page 283
For almost a half-century, cardiac pathologists
have focused on the atherosclerotic lesions under-
lying the thrombotic coronary occlusions responsi-
ble for STEMI. Postmortem examination of pa-
tients who died early after acute STEMI have
revealed principally 2 kinds of abnormalities. The
more common, described by Constantinides (2),
Davies et al. (3), and Falk (4) is the rupture of a thin
fibrous cap overlying a lipid-rich atherosclerotic
plaque, a so-called vulnerable plaque. In many
instances, there is evidence of inflammation in the
walls of the plaque, with macrophages and T
lymphocytes that secrete inhibitors of collagen syn-
thesis, and of proteases that digest the thin fibrous
cap. As a consequence of plaque rupture, tissue
factor is exposed to the flowing blood, and this in
turn causes activation of platelets and the coagula-
tion cascade. The coronary obstruction is caused in
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Strauss, MD, served as Guest Editor for this article.art by the plaque that encroaches on the arterial
umen and by the overlying thrombosis that delivers
he coup de grace and usually results in total luminal
cclusion. Prompt percutaneous coronary interven-
ion (PCI), with stent insertion, is the centerpiece
f therapy of these patients.
Plaque erosion, a second pathological lesion un-
erlying coronary thrombosis, has been studied by
an der Wal et al. (5) as well as Virmani et al. (6)
Dr. Virmani is one of the coauthors of the paper by
rati et al. [1]). Plaque erosion is responsible for the
evelopment of STEMI and/or sudden cardiac
eath in most of the patients who do not exhibit
laque rupture. These erosions are characterized by
n absent or disrupted endothelium overlying a
laque that is characterized by greater proliferation
f smooth muscle than inflammatory cells and by
he presence of abundant proteoglycans. Plaques
ith superficial erosions do not, by themselves,
ause critical obstruction. In such cases, the coro-
ary obstructions are precipitated largely by the
hrombi that develop on the dysfunctional intima.
ased on autopsy findings in patients who died
uddenly, endothelial plaque erosion may occur in
s many as 40% of patients with fatal coronary
hrombi (5,6). Plaque erosions appear to be more
ommon in younger women (younger than 50 years
f age) and in premenopausal smokers. Kubo et al.
7) characterized these lesions by optical coherence
omography (OCT) and reported that they are
haracterized by loss of endothelial lining with
ntimal tears.
The 31 patients described in the report by Prati
t al. (1) were studied relatively early in the devel-
pment of STEMI. After arteriography, which
evealed total coronary occlusion in 60% of these
atients, the investigators removed the offending
hrombi by aspiration thrombectomy and/or
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289thrombolysis. They then performed OCT, which
showed no evidence of residual, critically obstruc-
tive plaques. The decision of how these patients
would be treated was left to the interventional
cardiologists. Nineteen patients received the recom-
mended treatment of STEMI (i.e., stents were
deployed after aspiration thrombectomy). In the
other 12 patients, the operators apparently reasoned
that nothing might be gained by stenting an artery
without a severely obstructing plaque. Indeed, such
a procedure might even damage the arterial wall
unnecessarily and expose it to a stent, which carries
its own, albeit small, risk. Instead, they treated
these patients with aspirin, heparin, a thienopyri-
dine, and in some instances a glycoprotein IIb/IIIa
inhibitor. The residual coronary stenosis was similar
n the 2 groups. Remarkably, after a follow-up of 2
years, none of the 12 patients treated by thrombec-
tomy alone and only 1 of the 19 who received a stent
required an additional revascularization.
A number of questions should be addressed to
evaluate this novel approach to this sizable sub-
group of patients with early STEMI. 1) How often
are plaque erosions the culprit lesion in a contem-
porary sample of STEMI patients? 2) What are the
risks of PCI with stent implantation in patients
with plaque erosion compared with those with the
more commonly encountered flow-limiting rup-
tured plaque? 3) How much time is added to the
period of severe myocardial ischemia by interposing
OCT in patients in whom this procedure reveals a
ruptured plaque and who will require PCI with
stenting? 4) What is the balance of risk to benefit
by adding diagnostic OCT in patients with a
STEMI as opposed to simply proceeding with4. Falk E. Plaque rupture with severe
preexisting stenosis precipitating coro-
5
6
atherosclerotic lesi
Thromb Vasc Biol 20all patients with early STEMI, including those in
whom the thrombus occurs on an eroded plaque?
5) What is the optimal antithrombotic treatment
in patients who are not treated with a stent? 6) Could
the addition of a very low dose of the oral factor Xa
inhibitor rivaroxaban to an antiplatelet regimen be of
benefit? In the 15,526-patient ATLAS–TIMI 51
(Anti-Xa Therapy to Lower Cardiovascular Events
in Addition to Standard Therapy in Subjects with
Acute Coronary Syndrome–Thrombolysis in Myo-
cardial Infarction 51) trial of patients with acute
coronary syndromes, which included 7,817 patients
with STEMI, we observed that the addition of 2.5
mg twice daily of this anticoagulant, when added to
dual antiplatelet therapy and begun an average of 4
days after presentation, was associated with a robust
long-term reduction in mortality in STEMI pa-
tients. Although this regimen does cause some extra
bleeding, in appropriately selected patients, it was
not associated with fatal bleeding (8).
Although plaque erosion is not the most com-
mon cause, it certainly is not an infrequent cause of
coronary thrombosis and STEMI. OCT is a rela-
tively new imaging modality and is now being
introduced into a variety of clinical situations. Its
application by Prati et al. (1) in 12 patients with
STEMI secondary to plaque erosion who were
treated successfully without PCI should lead to
further investigation of this ingenious therapeutic
approach.
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